ReviewCureus2025
Perioperative Systemic Therapy in Localized Renal Cell Carcinoma: Current Evidence and Future Directions.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Localized renal cell carcinoma (RCC) carries a substantial risk of recurrence after nephrectomy, particularly in patients with adverse pathological features. Perioperative systemic therapy aims to eradicate micrometastatic disease. This review summarizes current evidence for neoadjuvant, adjuvant, and perioperative strategies in localized RCC, and outlines how emerging biological insights may reshape trial design and clinical practice. We conducted a narrative, non-systematic review of phase II-III studies and conference presentations through August 2025, examining trials that reported disease-free or recurrence-free and overall survival, perioperative feasibility, and translational endpoints, with data cross-checked against full texts and meeting abstracts. Adjuvant pembrolizumab improves disease-free and overall survival in selected high‑risk clear‑cell RCC and is now standard of care, whereas results from vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) and mTOR inhibitors have been inconsistent across trials, with most studies failing to demonstrate a survival benefit. Neoadjuvant immune checkpoint inhibitor (ICI), TKI, and immuno-oncology-tyrosine kinase inhibitor (IO-TKI) regimens are feasible and generally safe without delaying surgery; radiographic shrinkage is modest, but clinically meaningful surgical facilitation has been observed, particularly in cases with inferior vena cava tumor thrombus. To date, no randomized neoadjuvant trial has improved disease-free or overall survival, and the only completed phase III perioperative trial (PROSPER RCC) did not improve recurrence‑free survival, underscoring the need to better understand the optimal duration, timing, and patient selection for perioperative immunotherapy. Emerging biomarkers, including circulating KIM-1, ctDNA, and CD39
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.